应用受控衰减参数与肝脏硬度序列算法识别振动控制瞬时弹性成像不确定的MASLD治疗候选者
这项真实世界前瞻性研究纳入6中心1196例代谢功能障碍相关脂肪性肝病(MASLD)患者,利用配对振动控制瞬时弹性成像(VCTE)和肝活检数据,在肝脏硬度值8-12 kPa的不确定人群中建立算法识别显著纤维化(≥F2)。算法基于受控衰减参数280 dB/m阈值及不同肝脏硬度界值,在验证队列中重新分配36%的不确定病例,高风险组显著纤维化患病率达86%。
要点
- 在训练、内部验证和外部验证队列中,分别有33%、29%和31%的患者VCTE结果不确定。
- 受控衰减参数以280 dB/m为界可区分聚类,曲线下面积0.89(95%CI 0.86-0.97)。
- 受控衰减参数<280 dB/m时,肝脏硬度8.0-9.0 kPa排除显著纤维化的敏感性93%、阴性预测值91%。
核心结论
- 基于肝脏硬度和受控衰减参数阈值序列组合的算法,可优化不确定VCTE患者中中至晚期纤维化的诊断,从而识别MASLD治疗候选者。
研究设计与样本
- 真实世界前瞻性研究,纳入6个中心共1196例MASLD患者,均有配对VCTE和肝活检。
- 患者分为训练队列(西班牙3中心)、内部验证队列(西班牙2中心)和外部验证队列(美国1中心)。
- 采用高斯混合模型和k均值无监督聚类进行统计分析。
主要发现
- 训练、内部验证和外部验证样本中分别有33%、29%和31%的患者VCTE结果不确定。
- 受控衰减参数以280 dB/m为界可区分高斯混合模型聚类,曲线下面积0.89(95%CI 0.86-0.97)。
- 在受控衰减参数<280 dB/m的患者中,肝脏硬度8.0-9.0 kPa排除显著纤维化的敏感性为93%,阴性预测值为91%。
- 在受控衰减参数≥280 dB/m的患者中,肝脏硬度10.3-12.0 kPa诊断显著纤维化的特异性为91%。
- 在验证队列中应用该算法,36%的不确定VCTE病例被重新分配,重新分配的高风险组显著纤维化患病率为86%。
关键数值与推荐
- 显著纤维化定义为组织学分期≥F2。
- 不确定肝脏硬度测量定义为8-12 kPa。
- 受控衰减参数阈值280 dB/m(曲线下面积0.89;95%CI 0.86-0.97)。
- 受控衰减参数<280 dB/m时,肝脏硬度8.0-9.0 kPa用于排除显著纤维化(敏感性93%,阴性预测值91%)。
- 受控衰减参数≥280 dB/m时,肝脏硬度10.3-12.0 kPa用于诊断显著纤维化(特异性91%)。
临床怎么用
- 对于VCTE肝脏硬度在8-12 kPa的不确定MASLD患者,可依据受控衰减参数280 dB/m分层后,再结合相应肝脏硬度界值判断显著纤维化风险。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: A noteworthy proportion of patients with metabolic dysfunction-associated steatotic liver disease (MASLD) have an indeterminate vibration-controlled transient elastography (VCTE). Among these patients, we aimed to identify candidates for MASLD treatment by diagnosing significant fibrosis. METHODS: This was a real-world prospective study including a large dataset of MASLD patients with paired VCTE and liver biopsy from 6 centers. A total of 1196 patients were recruited and divided in training (3 centers, Spain), internal validation (2 centers, Spain), and external validation (1 center, United States) cohorts. In patients with indeterminate liver stiffness measurement (LSM) (8-12 kPa), a diagnostic algorithm was developed to identify significant fibrosis, defined as histological stage ≥F2. Statistical analysis was performed using Gaussian mixture model (GMM) and k-means unsupervised clusterization. RESULTS: From the eligible population, 33%, 29%, and 31% had indeterminate VCTE in the training, internal and external validation samples, respectively. The controlled attenuation parameter allowed the differentiation of GMM clusters with a cutoff of 280 dB/m (area under the curve, 0.89; 95% confidence interval, 0.86-0.97). Within patients with <280 dB/m, a LSM between 8.0-9.0 kPa showed a 93% sensitivity and a 91% negative predictive value to exclude significant fibrosis. Among patients with ≥280 dB/m, a LSM between 10.3 and 12.0 kPa diagnosed significant fibrosis with a 91% specificity. Applying this algorithm to the validation cohorts, 36% of the indeterminate VCTE were reallocated. The reallocated high-risk group showed a prevalence of 86% significant fibrosis, opening the therapeutic window for MASLD patients. CONCLUSIONS: To identify candidates for MASLD treatment among indeterminate VCTE, an algorithm-based on the sequential combination of LSM and controlled attenuation parameter thresholds can optimize the diagnosis of moderate-to-advanced fibrosis.
引用
- Marti-Aguado D, Carot-Sierra JM, Villalba-Ortiz A, et al. Identification of Candidates for MASLD Treatment With Indeterminate Vibration-Controlled Transient Elastography. Clin Gastroenterol Hepatol. 2024. PMID: 39551253. doi:10.1016/j.cgh.2024.10.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。